Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

RCT conducted at 33 sites in UK (n=15,187) reports that two-dose regimen of recombinant nanoparticle NVX-CoV2373 vaccine (Novavax) administered to adults conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 (alpha) variant (86.3%).

New England Journal of Medicine